Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 736,633 shares of RXRX, which is worth approximately $4.2 Million. The most recent transaction as insider was on Mar 08, 2023, when has been sold 70,890 shares (Class A Common Stock) at a price of $8.1 per share, resulting in proceeds of $574,209. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 737K

0.14% 3M change

10.16% 12M change

Total Value Held $4.2 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 08 2023	SELL Open market or private sale	$574,209 $8.1 p/Share	70,890 Reduced 6.85%	963,787 Class A Common Stock
Mar 08 2023	SELL Bona fide gift	-	10,000 Reduced 1.04%	953,787 Class A Common Stock
Mar 08 2023	BUY Exercise of conversion of derivative security	$232,500 $2.48 p/Share	93,750 Added 8.31%	1,034,677 Class A Common Stock
Mar 02 2023	SELL Bona fide gift	-	3,000 Reduced 0.31%	963,710 Class A Common Stock
Mar 02 2023	SELL Open market or private sale	$146,520 $7.92 p/Share	18,500 Reduced 1.93%	940,927 Class A Common Stock
Mar 02 2023	BUY Conversion of derivative security	-	3,000 Added 0.31%	966,710 Class A Common Stock
Mar 02 2023	BUY Conversion of derivative security	-	18,500 Added 1.9%	956,427 Class A Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$11,360 $8.44 p/Share	1,346 Reduced 0.14%	940,927 Class A Common Stock
Feb 02 2023	SELL Bona fide gift	-	3,000 Reduced 0.31%	963,710 Class A Common Stock
Feb 02 2023	SELL Open market or private sale	$170,570 $9.22 p/Share	18,500 Reduced 1.93%	942,273 Class A Common Stock
Feb 02 2023	BUY Conversion of derivative security	-	3,000 Added 0.31%	966,710 Class A Common Stock
Feb 02 2023	BUY Conversion of derivative security	-	18,500 Added 1.89%	960,773 Class A Common Stock
Feb 01 2023	SELL Payment of exercise price or tax liability	$11,816 $8.55 p/Share	1,382 Reduced 0.15%	942,273 Class A Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	417,850 Added 30.69%	943,655 Class A Common Stock
Jan 05 2023	SELL Bona fide gift	-	3,000 Reduced 0.31%	963,710 Class A Common Stock
Jan 05 2023	SELL Open market or private sale	$136,715 $7.39 p/Share	18,500 Reduced 3.4%	525,805 Class A Common Stock
Jan 05 2023	BUY Conversion of derivative security	-	3,000 Added 0.31%	966,710 Class A Common Stock
Jan 05 2023	BUY Conversion of derivative security	-	18,500 Added 3.29%	544,305 Class A Common Stock
Dec 14 2022	SELL Bona fide gift	-	3,000 Reduced 0.57%	525,805 Class A Common Stock
Dec 01 2022	SELL Open market or private sale	$336,006 $9.03 p/Share	37,210 Reduced 6.0%	582,805 Class A Common Stock
Dec 01 2022	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 4.94%	601,515 Class A Common Stock
Dec 01 2022	BUY Conversion of derivative security	-	18,500 Added 2.98%	601,305 Class A Common Stock
Nov 16 2022	SELL Bona fide gift	-	3,000 Reduced 0.56%	528,805 Class A Common Stock
Nov 15 2022	SELL Payment of exercise price or tax liability	$68,206 $11.86 p/Share	5,751 Reduced 1.0%	570,265 Class A Common Stock
Nov 03 2022	SELL Open market or private sale	$366,930 $10.0 p/Share	36,693 Reduced 5.99%	576,016 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account